OnKure Therapeutics Financials
This page shows OnKure Therapeutics (OKUR) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
OnKure operates as a cash-funded R&D platform where financing resets, not sales, do most of the balance-sheet shaping.
Between FY2023 and FY2024, cash jumped from$29.9M to$110.8M while total liabilities collapsed from$137.6M to$11.1M , effectively resetting a balance sheet that had been carrying negative equity. In FY2025, with financing cash flow only$163K , the-$51.9M free-cash outflow was absorbed almost entirely by that prior cash build, showing the company is now operating off money already raised rather than fresh annual funding.
The near-match between operating cash flow of
R&D remained the dominant spend at
Financial Health Signals
OnKure Therapeutics does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
OnKure Therapeutics passes 1 of 5 computable financial strength tests (4 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
OnKure Therapeutics reported a net loss of $59.5M while operations used $51.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
OnKure Therapeutics reported an operating loss of $63.0M against $3.4M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
OnKure Therapeutics's EBITDA was -$62.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 15.9% from the prior year.
OnKure Therapeutics reported -$59.5M in net income in fiscal year 2025. This represents a decrease of 13.0% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
OnKure Therapeutics recorded an outflow of $51.9M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 1.4% from the prior year.
OnKure Therapeutics held $59.0M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
OnKure Therapeutics's ROE was -105.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 55.2 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
OnKure Therapeutics invested $48.3M in research and development in fiscal year 2025. This represents an increase of 10.2% from the prior year.
OnKure Therapeutics invested $46K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 11.5% from the prior year.
Not reported for fiscal year 2025.
OKUR Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $12.6M+7.7% | $11.7M | N/A | $11.9M-5.5% | $12.6M-3.1% | $13.0M | N/A | $10.1M |
| SG&A Expenses | $4.3M+9.7% | $3.9M | N/A | $3.6M-3.4% | $3.7M-6.9% | $4.0M | N/A | $1.4M |
| Operating Income | -$16.9M-8.2% | -$15.6M | N/A | -$15.5M+5.0% | -$16.3M+4.0% | -$17.0M | N/A | -$11.5M |
| Interest Expense | $1.6M+239.1% | $458K | N/A | $802K-14.1% | $934K-13.1% | $1.1M | N/A | -$44K |
| Net Income | -$15.3M-1.2% | -$15.2M-12.2% | -$13.5M+8.1% | -$14.7M+4.5% | -$15.4M+3.4% | -$15.9M+8.7% | -$17.4M-50.9% | -$11.6M |
| EPS (Diluted) | -$0.31 | -$1.11 | -$0.99+9.2% | -$1.09+4.4% | -$1.14+4.2% | -$1.19 | -$10.05 | -$36.55 |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.
OKUR Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $179.4M-9.7% | $198.7M+219.9% | $62.1M-14.7% | $72.8M-15.4% | $86.1M-13.8% | $99.9M-13.1% | $114.9M+48.0% | $77.6M |
| Current Assets | $177.7M-10.0% | $197.5M+224.6% | $60.8M-14.9% | $71.5M-15.4% | $84.6M-13.9% | $98.2M-13.1% | $113.0M+46.8% | $77.0M |
| Cash & Equivalents | $166.5M-13.3% | $192.1M+225.3% | $59.0M-16.0% | $70.3M-15.6% | $83.4M-13.7% | $96.7M-12.7% | $110.8M+82.5% | $60.7M |
| Total Liabilities | $7.2M-49.5% | $14.3M+141.7% | $5.9M-7.4% | $6.4M-18.9% | $7.9M-14.4% | $9.2M-16.7% | $11.1M-94.8% | $212.7M |
| Current Liabilities | $6.6M-53.6% | $14.3M+142.0% | $5.9M-5.2% | $6.2M-17.8% | $7.6M-13.5% | $8.8M-16.6% | $10.5M+224.2% | $3.2M |
| Total Equity | $172.1M-6.6% | $184.4M+228.1% | $56.2M-15.4% | $66.4M-15.0% | $78.2M-13.8% | $90.6M-12.7% | $103.8M+176.9% | -$135.1M |
| Retained Earnings | -$244.7M-6.7% | -$229.4M-7.1% | -$214.2M-6.7% | -$200.7M-7.9% | -$186.0M-9.0% | -$170.6M-10.3% | -$154.7M+34.4% | -$236.0M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
OKUR Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$10.4M+20.0% | -$12.9M-12.4% | -$11.5M+11.7% | -$13.0M+1.8% | -$13.3M+5.2% | -$14.0M+40.0% | -$23.4M-119.1% | -$10.7M |
| Capital Expenditures | $3K-40.0% | $5K-44.4% | $9K+50.0% | $6K-53.8% | $13K-27.8% | $18K+20.0% | $15K-16.7% | $18K |
| Free Cash Flow | -$10.4M+20.0% | -$12.9M-12.3% | -$11.5M+11.7% | -$13.0M+1.8% | -$13.3M+5.2% | -$14.0M+40.0% | -$23.4M-118.8% | -$10.7M |
| Investing Cash Flow | -$9.9M-197300.0% | -$5K+44.4% | -$9K-50.0% | -$6K+53.8% | -$13K+27.8% | -$18K-100.1% | $15.9M+88488.9% | -$18K |
| Financing Cash Flow | -$5.4M-103.7% | $146.0M+60732.9% | $240K | $0 | $0+100.0% | -$77K-100.1% | $110.2M+2204820.0% | $5K |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
OKUR Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -8.9%-0.7pp | -8.2%+15.8pp | -24.0%-1.9pp | -22.1%-2.4pp | -19.7%-2.1pp | -17.6%-0.8pp | -16.8% | N/A |
| Return on Assets | -8.6%-0.9pp | -7.6%+14.1pp | -21.7%-1.6pp | -20.2%-2.3pp | -17.9%-1.9pp | -15.9%-0.8pp | -15.2%-0.3pp | -14.9% |
| Current Ratio | 26.75+13.0x | 13.78+3.5x | 10.28-1.2x | 11.45+0.3x | 11.130.0x | 11.18+0.4x | 10.73-13.0x | 23.71 |
| Debt-to-Equity | 0.040.0x | 0.080.0x | 0.110.0x | 0.100.0x | 0.100.0x | 0.100.0x | 0.11 | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where OnKure Therapeutics Ranks
Frequently Asked Questions
Is OnKure Therapeutics profitable?
No, OnKure Therapeutics (OKUR) reported a net income of -$59.5M in fiscal year 2025.
What is OnKure Therapeutics's EBITDA?
OnKure Therapeutics (OKUR) had EBITDA of -$62.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is OnKure Therapeutics's return on equity (ROE)?
OnKure Therapeutics (OKUR) has a return on equity of -105.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is OnKure Therapeutics's free cash flow?
OnKure Therapeutics (OKUR) recorded an outflow of $51.9M in free cash flow during fiscal year 2025. This represents a -1.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is OnKure Therapeutics's operating cash flow?
OnKure Therapeutics (OKUR) recorded an outflow of $51.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are OnKure Therapeutics's total assets?
OnKure Therapeutics (OKUR) had $62.1M in total assets as of fiscal year 2025, including both current and long-term assets.
What are OnKure Therapeutics's capital expenditures?
OnKure Therapeutics (OKUR) invested $46K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does OnKure Therapeutics spend on research and development?
OnKure Therapeutics (OKUR) invested $48.3M in research and development during fiscal year 2025.
What is OnKure Therapeutics's current ratio?
OnKure Therapeutics (OKUR) had a current ratio of 10.28 as of fiscal year 2025, which is generally considered healthy.
What is OnKure Therapeutics's debt-to-equity ratio?
OnKure Therapeutics (OKUR) had a debt-to-equity ratio of 0.11 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is OnKure Therapeutics's return on assets (ROA)?
OnKure Therapeutics (OKUR) had a return on assets of -95.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does OnKure Therapeutics's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, OnKure Therapeutics (OKUR) held $59.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $51.8M over that year. Dividing the one by the other, the reported balance equals about 14 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is OnKure Therapeutics's Piotroski F-Score?
OnKure Therapeutics (OKUR) has a Piotroski F-Score of 1 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are OnKure Therapeutics's earnings high quality?
OnKure Therapeutics (OKUR) reported a net loss of $59.5M while operations used $51.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can OnKure Therapeutics cover its interest payments?
OnKure Therapeutics (OKUR) reported an operating loss of $63.0M against $3.4M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.